Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

Medical Officer. "We continue to believe that interferon remains the greatest impediment to care for a majority of the millions of individuals living with HCV.  PSI-7977 has demonstrated high cure rates, without viral resistance, and across HCV genotypes; we hope to confirm these benefits in these registrational studies."

About FISSON

FISSION will be conducted at more than 100 centers in the US, Europe and other territories. The trial will enroll approximately 500 treatment-naive patients with HCV genotype 2 or 3 into one of two open-label regimens:

  • PSI-7977 400 mg QD with ribavirin for 12 weeks
  • the current standard-of-care for HCV GT2/3, pegylated interferon and ribavirin for 24 weeks

The study will include patients with and without cirrhosis, and will enroll a greater proportion of patients with HCV genotype 3, who are less likely to achieve an SVR with the currently available therapy, pegylated interferon and ribavirin.  The primary endpoint of the trial will be SVR12. Enrollment is anticipated to begin by the end of 2011.

About POSITRON

POSITRON will be conducted at more than 100 centers in the US, Europe and other territories.  The trial will enroll patients with HCV genotype 2 or 3 who cannot take interferon into one of two blinded regimens:

  • PSI-7977 400 mg QD with ribavirin for 12 weeks
  • placebo PSI-7977 and placebo ribavirin

POSITRON will enroll approximately 225 patients with or without cirrhosis.  The primary endpoint of the trial will be SVR12. Enrollment is anticipated to begin in the first quarter of 2012.

About NEUTRINO

NEUTRINO will enroll approximately 280 patients who cannot take interferon. The study will be conducted at more than 100 centers in the US, Europe and other territories. The final design of the trial will be based on em
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
(Date:7/30/2015)... 30, 2015  ResMed (NYSE: RMD ... definitive agreement to acquire Curative Medical, a ... sleep-disordered breathing medical devices and accessories. ... with ResMed,s global leadership in sleep and respiratory medicine, ... China suffering from sleep-disordered breathing ...
(Date:7/30/2015)... we bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. ... Medicare resources and continue highlighting the success of the prescription drug benefit, commonly referred ... out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... -- URINOZINC® Prostate Formula Added to GNC Live ... The original, patented, URINOZINC® Prostate Formula ... Well stores and at select GNC franchise stores. ... stores spread over 49 countries worldwide. URINOZINC® is ...
... LONDON, June 14, 2011 MGT Capital Investments, Inc. (NYSE ... 8, 2011 it received notice from the NYSE Amex (the ... following Exchange continued listing standards:  Section 1003(a)(i) of the Company ... less than $2,000,000 and losses from continuing operations and/or net ...
Cached Medicine Technology:Patented URINOZINC® Prostate Formula Now Available at GNC Stores 2Patented URINOZINC® Prostate Formula Now Available at GNC Stores 3MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification 2MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged ... women often causing pain and discomfort. Those who spend a lot of time on ... Houston Vein Center is doing what it can to create awareness and provide a ...
(Date:8/1/2015)... ME (PRWEB) , ... August 01, 2015 , ... Tina ... Retail Champions.” , Wilcoxson was given that honor by the National Retail Federation, the ... retail industry. Wilcoxson was one of three Maine business owners to be named as ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — ... portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... the Moores UCSD Cancer Center and the Arizona Oncology Services ... the Strut-Adjusted Volume Implant (SAVI) controls the rate of cancer ... brachytherapy. This study also demonstrates the accuracy and flexibility of ... and minimize the exposure of healthy surrounding tissue and organs. ...
... N.J. (July 12, 2010) A new study by ... University Medical Center sheds light on how bortezomib (VELCADE), ... known as proteasome inhibitors, works in mantle cell lymphoma. ... might benefit most from bortezomib. Additionally, researchers demonstrate that ...
... 2010 In an effort that will contribute ... Philippines and surrounding regions, the Laboratory Services Division ... (FDA) has attained the internationally recognized accreditation for ... International Electrotechnical Commission (ISO/IEC) 17025:2005. The FDA celebrates ...
... LANSING, Mich., July 12, 2010 Drinking tart cherry juice ... spent awake after going to sleep, according to a new ... 1 . A team of University of Pennsylvania, University ... pilot study on the sleep habits of 15 older adults. ...
... Starting in February 2011, Springer will publish a new ... . Focusing exclusively on translational aspects of drug ... for publication of high-quality research. It is an ... Drug Delivery and Translational Research will publish ...
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
Cached Medicine News:Health News:Radiation device allows for targeted breast radiation to control cancer 2Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 2Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 3Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 4Health News:Medicine quality in Philippines and region strengthened with Philippine FDA's accreditation 2Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Springer launches Drug Delivery and Translational Research 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
Medicine Products: